

Antigenic Variation of Avian Influenza A(H5N6) Viruses, Guangdong Province, China, 2014–2018

Ru Bai,¹ Reina S. Sikkema,¹ Cong rong Li, Bas B. Oude Munnink, Jie Wu, Lirong Zou, Yi Jing, Jing Lu, Runyu Yuan, Ming Liao, Marion P.G. Koopmans,¹ Chang-wen Ke¹

Market surveillance showed continuing circulation of avian influenza A(H5N6) virus in live poultry markets in Guangdong Province in 2017, despite compulsory vaccination for avian influenza A(H5Nx) and A(H7N9). We analyzed H5N6 viruses from 2014–2018 from Guangdong Province, revealing antigenic drift and decreased antibody response against the vaccine strain in vaccinated chickens.

Human disease from low-pathogenic influenza A(H7N9) infection was first reported in 2013, and a total of 1,567 human cases have been reported (1). During the fifth wave, which started in October 2016, the number of human cases increased steeply, the virus spread into western provinces of China, and a highly pathogenic avian influenza (HPAI) A(H7N9) variant emerged (2). In parallel, HPAI H5 subtype viruses (clade 2.3.4.4 H5Nx) were causing international outbreaks in poultry (3,4) and infecting humans in China (5,6). In July 2017, Guangdong Province implemented a compulsory vaccination strategy for poultry (chickens, ducks, geese, quail, pigeons, and rare birds in captivity) using the combined inactivated influenza vaccine (H5 A/chicken/Guizhou/4/2013 [Re-8] + H7 A/pigeon/Shanghai/S1069/2013 [Re-1]) to prevent the dissemination of HPAI A(H7N9) and A(H5Nx) viruses (7).

Our market surveillance showed that H7N9 viruses almost disappeared from live poultry markets (LPMs), although low-level circulation in poultry and the environment, as well as sporadic human cases, are still reported throughout China (8,9). However, during the same period, H5N6 subtype viruses continued to circulate in LPMs. We report our investigation of the prevalence, evolution, and antigenic variation of H5N6 viruses during 2014–2018 in Guangdong Province.

Author affiliations: Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China (R. Bai, C. Li, J. Wu, L. Zou, Y. Jing, J. Lu, R. Yuan, C. Ke); Erasmus Medical Centre, Rotterdam, the Netherlands (R.S. Sikkema, B.B. Oude Munnink, M.P.G. Koopmans); Southern Medical University Guangzhou (C. Li, Y. Jing, C. Ke); South China Agricultural University, Guangzhou (M. Liao)

The Study

To investigate the emergence and spread of HPAI H7N9 and H5Nx viruses in LPMs, we collected environmental and poultry samples and a throat swab from an H5N6-infected person in September 2018. We tested samples using reverse transcription PCR (RT-PCR) and real-time RT-PCR (rRT-PCR) to distinguish between subtypes H5 and H7. During January 2016–October 2018, a total of 52,387 environmental samples were collected, of which 1,627 (3.1%) were positive for H5 and 1,303 (2.5%) for H7. All H7-positive samples were of the H7N9 subtype, and 99% of H5-positive samples were of the H5N6 subtype (Figure 1; Appendix 1 Table 1, <https://wwwnc.cdc.gov/EID/article/25/10/19-0274-App1.pdf>). After implementation of poultry vaccination the rate of H7N9 virus-positive samples decreased from 12.8% to 0%, and the average positivity rate for H5-subtype viruses remained ≈20% (Figure 1; Appendix 1 Table 1).

We cultured 883 H5 subtype-positive samples, including the human H5N6 sample. Virus cultivation was successful for 147 environmental samples, 21 poultry samples, and the human sample. We selected 73 H5N6 isolates that were amplified successfully for whole-genome sequencing using the Ion PGM system and the PathAmp FluA reagents (Life Technologies, <https://www.thermofisher.com>). We analyzed data using CLC Genomics Workbench 7.5.1 software (QIAGEN, <https://www.qiagenbioinformatics.com>).

We combined genome sequences from this study with all sequences of H5N6 viruses from China, as well as H3 and H6 subtype viruses available in GenBank and the GISAID database (<https://www.gisaid.org>) for 1996–2018 (Appendix 2 Tables 1, 2, <https://wwwnc.cdc.gov/EID/article/25/10/19-0274-App2.xlsx>). For sequencing, we used MUSCLE version 3.5 (10) and phylogenetic analysis under the general time reversible plus invariant sites plus Γ 4 model (hemagglutinin [HA], neuraminidase [NA], polymerase basic [PB] 1, PB2, polymerase acidic [PA], nucleoprotein [NP]) and the transversion model plus F plus invariant sites plus Γ 4 model (matrix [M], nonstructural [NS]), performed using IQ-TREE (11). Phylogenetic analysis showed that all H5N6 viruses isolated in Guangdong Province descended from the H5N6 viruses that circulated in the province during 2015–2016. However, the currently circulating H5N6




Figure 1. Proportion of H5 (blue bars) and H7 (red bars) subtypes in avian influenza A virus–positive samples (dashed line) from live poultry markets, Guangdong Province, China, January 2013–October 2018. Re-8, A/chicken/Guizhou/4/2013 (Re-8); Re-1, H7 A/pigeon/Shanghai/S1069/2013 (Re-1).

viruses in Guangdong Province cluster separately from the A/chicken/Guizhou/4/2013 (Re-8) vaccine strain, based on HA sequences (Figure 2). All N6 genes belong to the Eurasian lineage. Both HA and NA genes of the human H5N6 virus clustered with the H5N6 viruses found in the environment and poultry in our study (Appendix 1 Figure).

We classified both surface and internal genes of HPAI H5N6 viruses from Guangdong Province into different sublineages according to tree topology and bootstrap values of >85% and further classified the HA and NA genes into 4 subgroups (Figure 2). Phylogeny of the internal genes of the recent clade 2.3.4.4 H5N6 viruses showed they evolved from H5N1 viruses from 2013–2014, in which, from 2015 onward, almost all PB2 genes were replaced by H6 subtype–origin PB2 genes. Substitution of the PB2 gene can change the virulence and pathogenicity in mammals and in different bird species (12). Moreover, from 2016 onward, H5N6 acquired PB1 and PA genes from (avian) H3-like or LPAI gene pools. In 2017, NP, M, and NS genes from H3-like viruses and local LPAI gene pools were first detected in circulating H5N6 viruses (Figure 2). Closely related H5N6 viruses from China with similar internal gene composition did not show any intravenous pathogenicity in ducks and lower intravenous pathogenicity in chickens (13), which could explain the widespread circulation of H5N6 viruses in Guangdong Province.

When we compared the HA gene predicted receptor binding sites and other regions of the H5N6 isolates from Guangdong Province with A/chicken/Guizhou/4/2013 (Re-8), we found 35 positions where >50% of viruses in our study had amino acid substitutions (4). Those mutations (H3 numbering) occurred in sites R50K, D63N, R81S, S94A/T, L122Q, S125R/K, P128S, D129N/S, D130 deletion/E/T, T131S, L133 deletion/S, A137T, A138S, Q142K, M144V, P145A, I155T, N158S, T160A, R173G/K, S185P, N187S, A188V, A189E,

T192A, N193D/K/T/N, T199A/I, R227S/C/Q/G, K238R, V260I, K262T, M272I, H276K/N/Q/S, N278S, and N323S (Appendix 1 Table 2). In addition, we detected several mutations that were exclusively found in >90% of the most recent H5N6 isolates from Guangdong Province (2017–2018), including L122Q, S125R/K, P128S, P145A, K262T, M272I, H276K/N/Q/S, and N401I/S/N. We identified 3 new amino acid substitutions in the NA and PB2 genes of human H5N6 isolate: the Q136H on the NA gene, which might affect its susceptibility to antiviral neuraminidase inhibitors (4), and mutation E627V and A588V in the PB2 gene, of which the influence on its virulence in mammals needs further investigation (4). Furthermore, we found A588V mutations in 64 of 68 PB2 genes of H5N6 viruses from the environment.

We determined HI titers in serum of H5 A/chicken/Guizhou/4/2013 (Re-8)–vaccinated chickens ($n = 5$) and serum from the H5N6 virus–infected human patient to human and environmental H5N6 viral isolates from different time points using a standard protocol (14). Serum from chickens vaccinated with H5 A/chicken/Guizhou/4/2013 (Re-8) showed high titers ($8–10 \log_2$) to the human H5N6 isolates from 2014–2017 and lower titers ($4–6 \log_2$) to the human H5N6 isolate from 2018. We observed a similar trend when using environmental isolates for the HI assays. Conversely, serum from the H5N6–infected human in 2018 showed higher titers to human H5N6 isolates in 2017 and 2018 ($6 \log_2$) than to those from 2014 and 2015 ($4 \log_2$) (Table).

Conclusions

Compulsory vaccination of the combined inactivated influenza vaccine was implemented in Guangdong Province in July 2017. Although the prevalence of H7N9 in LPMs decreased abruptly, we revealed uninterrupted circulation of H5N6 viruses in LPMs after implementation of the




Figure 2. Phylogeny of influenza A(H5N6) viruses collected in Guangdong Province, China, January 2013–October 2018, compared with reference isolates. A) Viruses of clade 2.3.4.4 H5N6 viruses are divided into 4 subgroups (I–IV) on the basis of the surface genes (HA and NA). Colors in key distinguish surface and internal genes. The A/chicken/Guizhou/4/2013 (Re-8) vaccine strain and viral strains used for HI testing are labeled. The 2018 human H5N6 isolate from Guangdong Province is blue, human H5N6 virus sequences since 2013 are purple, human and environmental H5N6 isolates used for the HI test are labeled with a purple dot (except for HA256 human strain, for which no sequence was available). The top part of the tree containing the bulk of the Guangdong Province recent H5N6 viruses and the human case is highlighted with a red box. All branch lengths are scaled according to the number of substitutions per site. Scale bars indicate nucleotide substitutions per site. GD, Guangdong; HA, hemagglutinin gene; LPAIV, low pathogenicity avian influenza virus; NA, neuraminidase gene; 1, polymerase basic 2 gene; 2, polymerase basic 1 gene; 3, polymerase acidic gene; 5, nucleoprotein gene; 7, matrix gene; 8, nonstructural gene. B) An expansion of the phylogenetic tree in the red outlined box of panel A. The sequence in blue is the newly approved vaccine strain 18SF020.

vaccination strategy. Our study shows that H5N6 viruses in Guangdong Province show antigenic drift when compared with the A/chicken/Guizhou/4/2013 (Re-8) vaccine strain, resulting in lower protection of vaccinated chickens against circulating clade 2.3.4.4 H5 viruses. In December 2018, the China government approved a new poultry vaccine (H5 A/duck/Guizhou/S4184/2017 [Re-11], H5 A/chicken/Liaoning/SD007/2017 [Re-12] + H7 A/chicken/Guangxi/SD098/2017 [Re-2]). Moreover, the World Health Organization proposed a new A/Guangdong/18SF020/2018-like H5N6 candidate vaccine virus, which was partly based on strain A/Guangdong/18SF020/2018 reported in this study (15).

Vaccine escape variants remain a risk for human and animal health. Therefore, future policy should focus on preventing the spread of avian influenza viruses along the market chain by strengthening farm-level surveillance and biosecurity, as well as implementing measures to monitor and prevent the spread of avian influenza viruses that have zoonotic potential in the market chain.

Acknowledgments

We thank the 21 collaborating laboratories in Guangdong Province that participated in the longitudinal surveillance.

This work was supported by grants from the National Key Research and Development Program of China (grant

Table. HI titers of influenza A(H5N6) virus strains collected during 2014–2018 in Guangdong Province, China, compared with vaccine strains*

Virus strain†	Sample type	Collection date	HI titers					H5N6-infected
			Postvaccination chicken serum					human serum
			S1	S2	S3	S4	S5	S6
39715	Human	2014 Dec 11	512	512	1024	512	256	16
ZQ874	Human	2015 Dec 31	512	512	512	512	256	16
HA256	Human	2017 Jun 30‡	256	256	512	256	256	64
18SF020-1	Human	2018 Sep 30	32	16	64	32	16	64
C17280709	Environment	2017 May 2	64	64	128	128	64	16
C18277136	Environment	2018 Apr 2	64	32	32	64	16	16
C18285099	Environment	2018 Feb 28	32	32	NT	NT	32	8
PO17284158	Waterfowl	2018 May 10	128	64	NT	NT	NT	NT
A§	Chicken	2018 Nov 19¶	2,048	1,024	4,096	1,024	1,024	NT
B#	Chicken	2018 Sep 20**	32	32	NT	NT	NT	NT

*NT, not tested; S, sample no.

†The name of virus strain is the abbreviation of the original name for each viral isolate.

‡Date isolate received.

§Vaccine strain A/chicken/Guizhou/4/2013 (Re-8) + H7 A/pigeon/Shanghai/S1069/2013 (Re-1).

¶Date vaccine strain tested.

#Vaccine strain H5 A/duck/Guangdong/S1322/2010 (Re-6).

**Date vaccine strain received.

2016YFC1200201), the European Commission's H2020 program under contract number 643476 (<http://www.compare-europe.eu>), and the Royal Netherlands Academy of Arts and Sciences (project number 530-6CDP23).

About the Author

Dr. Bai is a postdoctoral researcher at the Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China, whose research focuses on the epidemiology, evolution, and transmission of avian influenza viruses in Guangdong Province. Ms. Sikkema is a PhD candidate at the Erasmus Medical Centre, Rotterdam, the Netherlands, whose research focuses on the risk-based surveillance of influenza viruses in the market chain.

References

- World Health Organization. Influenza at the human-animal interface Summary and assessment, 26 January to 2 March 2018. 2018 Mar 2 [cited 2019 May 7], https://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_02_03_2018.pdf?ua=1
- Su S, Gu M, Liu D, Cui J, Gao GF, Zhou J, et al. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. *Trends Microbiol.* 2017;25:713–28. <https://doi.org/10.1016/j.tim.2017.06.008>
- Poen MJ, Venkatesh D, Bestebroer TM, Vuong O, Scheuer RD, et al. Co-circulation of genetically distinct highly pathogenic avian influenza A clade 2.3.4.4 (H5N6) viruses in wild waterfowl and poultry in Europe and East Asia, 2017–18. *Virus Evol.* 2019; 22:5(1).
- Bi Y, Chen Q, Wang Q, Chen J, Jin T, et al. Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in China. *Cell Host Microbe.* 2016;20:810–21. <https://doi.org/10.1016/j.chom.2016.10.022>
- Yang ZF, Mok CK, Peiris JS, Zhong NS. Human infection with a novel avian influenza A(H5N6) virus. *N Engl J Med.* 2015;373:487–9. <https://doi.org/10.1056/NEJMc1502983>
- Bi Y, Tan S, Yang Y, Wong G, Zhao M, Zhang Q, et al. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. *Clin Infect Dis.* 2019;68:1100–9. <https://doi.org/10.1093/cid/ciy681>
- Food and Agriculture Organization of the United Nations (FAO). Chinese-origin H7N9 avian influenza spread in poultry and human exposure. 2018 Feb 18 [cited 2019 May 7]. <http://www.fao.org/3/i8705en/i8705EN.PDF>
- Wu J, Ke C, Lau EHY, Song Y, Cheng KL, Zou L, et al. Influenza H5/H7 virus vaccination in poultry and reduction of zoonotic infections, Guangdong province, China, 2017–18. *Emerg Infect Dis.* 2019;25:116–8. <https://doi.org/10.3201/eid2501.181259>
- Food and Agriculture of Organization of the United Nations. FAO H7N9 situation update, 2019 May 8 [cited 2019 Jun 13]. http://www.fao.org/ag/againfo/programmes/en/empres/H7N9/wave_7/Situation_update_2019_05_08.html
- Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 2004;32:1792–7. <https://doi.org/10.1093/nar/gkh340>
- Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* 2015;32:268–74. <https://doi.org/10.1093/molbev/msu300>
- Tada T, Suzuki K, Sakurai Y, Kubo M, Okada H et al. NP Body Domain and PB2 Contribute to Increased Virulence of H5N1 Highly Pathogenic Avian Influenza Viruses in Chickens. *J Virol.* 2011; 85(4):1834–46.14.
- Sun W, Li J, Hu J, Jiang D, Xing C, Zhan T, et al. Genetic analysis and biological characteristics of different internal gene origin H5N6 reassortment avian influenza virus in China in 2016. *Vet Microbiol.* 2018;219:200–11. <https://doi.org/10.1016/j.vetmic.2018.04.023>
- Killian ML. Hemagglutination assay for the avian influenza virus. In: Spackman E, editor. *Avian influenza virus*. New York: Springer; 2008. p. 47–52.
- World Health Organization, Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness, 2019 February 21 [cited 2019 August 20] https://www.who.int/influenza/vaccines/virus/201902_zoonotic_vaccinevirusupdate.pdf?ua=1

Address for correspondence: Chang-wen Ke, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China; email: kecw1965@aliyun.com; Marion P.G. Koopmans, Erasmus Medical Centre, Viroscience Department, Rotterdam, the Netherlands; email: m.koopmans@erasmusmc.nl

Antigenic Variation of Avian Influenza A(H5N6) Viruses, Guangdong Province, China, 2014–2018

Appendix 1

Appendix 1 Table 1. Epidemiologic surveillance of H5, H7, and avian influenza A viruses, Guangdong province, China, January 2013–October 2018*

Time	No. tested samples	FluA+, no. (%)	H5/FluA+, no. (%)	H7/FluA+, no. (%)
Jan 2013	108	51 (47.22)	6 (11.76)	0 (0)
Feb 2013	81	23 (28.4)	1 (4.35)	0 (0)
Mar 2013	126	38 (30.16)	4 (10.53)	0 (0)
Apr 2013	230	74 (32.17)	23 (31.08)	0 (0)
May 2013	339	72 (21.24)	1 (1.39)	0 (0)
June 2013	182	15 (8.24)	1 (6.67)	0 (0)
July 2013	184	41 (22.28)	13 (31.71)	0 (0)
Aug 2013	256	66 (25.78)	1 (1.52)	0 (0)
Sept 2013	194	47 (24.23)	7 (14.89)	0 (0)
Oct 2013	196	51 (26.02)	21 (41.18)	1 (1.96)
Nov 2013	261	75 (28.74)	15 (20)	0 (0)
Dec 2013	656	242 (36.89)	61 (25.21)	58 (23.97)
Jan 2014	1,978	457 (23.1)	56 (12.25)	136 (29.76)
Feb 2014	1,800	464 (25.78)	44 (9.48)	160 (34.48)
Mar 2014	1,499	437 (29.15)	73 (16.7)	169 (38.67)
Apr 2014	1,436	328 (22.84)	45 (13.72)	94 (28.66)
May 2014	852	172 (20.19)	27 (15.7)	37 (21.51)
June 2014	489	147 (30.06)	20 (13.61)	31 (21.09)
July 2014	403	109 (27.05)	32 (29.36)	21 (19.27)
Aug 2014	403	126 (31.27)	15 (11.9)	7 (5.56)
Sept 2014	386	155 (40.16)	6 (3.87)	0 (0)
Oct 2014	401	151 (37.66)	29 (19.21)	3 (1.99)
Nov 2014	953	336 (35.26)	70 (20.83)	39 (11.61)
Dec 2014	1,377	548 (39.8)	91 (16.61)	59 (10.77)
Jan 2015	3,776	987 (26.14)	140 (14.18)	283 (28.67)
Feb 2015	3,279	655 (19.98)	63 (9.62)	235 (35.88)
Mar 2015	3,206	464 (14.47)	47 (10.13)	88 (18.97)
Apr 2015	2,689	526 (19.56)	76 (14.45)	27 (5.13)
May 2015	2,236	365 (16.32)	37 (10.14)	23 (6.3)
June 2015	934	139 (14.88)	22 (15.83)	6 (4.32)
July 2015	623	117 (18.78)	18 (15.38)	0 (0)
Aug 2015	758	119 (15.7)	17 (14.29)	2 (1.68)
Sept 2015	617	105 (17.02)	13 (12.38)	2 (1.9)
Oct 2015	636	121 (19.03)	26 (21.49)	0 (0)
Nov 2015	1,407	361 (25.66)	62 (17.17)	2 (0.55)
Dec 2015	2,080	644 (30.96)	122 (18.94)	9 (1.4)
Jan 2016	2,523	743 (29.45)	161 (21.67)	50 (6.73)
Feb 2016	2,186	537 (24.57)	81 (15.08)	52 (9.68)
Mar 2016	2,203	611 (27.73)	109 (17.84)	84 (13.75)
Apr 2016	1,755	342 (19.49)	55 (16.08)	12 (3.51)
May 2016	1,867	430 (23.03)	54 (12.56)	17 (3.95)
June 2016	625	85 (13.6)	11 (12.94)	3 (3.53)
July 2016	596	105 (17.62)	7 (6.67)	2 (1.9)
Aug 2016	750	132 (17.6)	15 (11.36)	0 (0)
Sept 2016	572	97 (16.96)	19 (19.59)	1 (1.03)
Oct 2016	712	99 (13.9)	4 (4.04)	4 (4.04)
Nov 2016	1,852	421 (22.73)	52 (12.35)	27 (6.41)
Dec 2016	2,590	686 (26.49)	81 (11.81)	206 (30.03)
Jan 2017	3,790	708 (18.68)	58 (8.19)	260 (36.72)
Feb 2017	3,341	672 (20.11)	31 (4.61)	247 (36.76)

Time	No. tested samples	FluA+, no. (%)	H5/FluA+, no. (%)	H7/FluA+, no. (%)
Mar 2017	3,062	507 (16.56)	33 (6.51)	131 (25.84)
Apr 2017	1,910	355 (18.59)	59 (16.62)	101 (28.45)
May 2017	1,960	286 (14.59)	44 (15.38)	38 (13.29)
June 2017	599	55 (9.18)	6 (10.91)	12 (21.82)
July 2017	632	47 (7.44)	17 (36.17)	6 (12.77)
Aug 2017	581	90 (15.49)	10 (11.11)	0 (0)
Sept 2017	631	94 (14.9)	13 (13.83)	2 (2.13)
Oct 2017	809	168 (20.77)	37 (22.02)	0 (0)
Nov 2017	1,831	501 (27.36)	101 (20.16)	1 (0.2)
Dec 2017	1,758	412 (23.44)	100 (24.27)	11 (2.67)
Jan 2018	2,164	561 (25.92)	134 (23.89)	22 (3.92)
Feb 2018	1,892	324 (17.12)	62 (19.14)	8 (2.47)
Mar 2018	1,751	239 (13.65)	32 (13.39)	5 (2.09)
Apr 2018	1,776	262 (14.75)	35 (13.36)	1 (0.38)
May 2018	1,929	283 (14.67)	27 (9.54)	0 (0)
June 2018	655	69 (10.53)	11 (15.94)	0 (0)
July 2018	705	111 (15.74)	28 (25.23)	0 (0)
Aug 2018	656	141 (21.49)	31 (21.99)	0 (0)
Sept 2018	791	237 (29.96)	58 (24.47)	0 (0)
Oct 2018	933	160 (17.15)	51 (31.88)	0 (0)
Total	8,9418	19,398 (15.73)	2,932 (11.08)	2,795 (6.28)


*Flu A+, type A avian influenza viruses; H5, H5 subtype avian influenza virus; H7, H7 subtype avian influenza virus.

Appendix 1 Table 2. Amino acid substitution of the hemagglutinin protein of influenza A(5N6) viruses from human and environment compared with vaccine strain A/Chicken/Guizhou/4/2013 (Re-8) (H3 numbering)


Molecular feature or amino acid substitution	Amino acids of viruses (no.)		
	Re-8 (1)	Human (1)	Environment (72)
Multibasic cleavage site PLRERRRKR↓G			
Amino acid substitution			
R50K	R	K	K (67), R(5)
D63N	D	N	D (47), N (25)
R81S	R	S	R (26), S (46)
S94A/T	S	A	A (68), T (4)
L122Q	L	Q	L (7), Q (65)
S125R/K	S	R	R (57), K (2), S (13)
P128S	P	S	S (59), P (13)
D129N/S	D	N	N (69), S (3)
D130bdeletion/E/T	D	-	65 (-), E (5), T (2)
T131S	T	T	T (70), S (2)
L133 deletion/S	L	S	7 (-), S (65)
A137T	A	A	T (1), A (71)
A138S	A	A	S (1), A (71)
Q142K	Q	Q	Q (67), K (5)
M144V	M	V	V (70), M (2)
P145A	P	A	A (59), P (13)
I155T	I	T	T (72)
N158S	N	N	S (1), N (71)
T160A	T	A	A (72)
R173G/K	R	K	G (5), K (56),
S185P	S	S	P (3), S (69)
N187S	N	S	S (60), N (12)
A188V	A	A	V (1), A (71)
A189E	A	E	E (71), A (1)
T192A	T	T	A (8), T (64)
N193D/K/T/N	N	D	D (26), K (10), T (1), N (35)
T199A/I	T	T	T (70), I (1), A (1)
R227S/C/Q/G	R	R	S (4), C (2), Q (5), R (58), G (3)
K238R	K	R	R (62), K (10)
V260I	V	I	I (67), V (5)
K262T	K	T	T (67), K (5)
M272I	M	I	I (63), M (9)
H276K/N/Q/S	H	N	K (2), N (60), Q (1), S (5), H (4)
N278S	N	N	N (71), S (1)
N323S	N	S	S (72)

*-, deletion.

A




B




C




D




E




F



G



H



Appendix 1 Figure. Maximum-likelihood phylogenetic trees for the HA, NA, PB2, PB1, PA, NP, M, and NS genes of A(H5N6) avian influenza viruses. The viruses from the environment in this study are highlighted in red; the human case is highlighted in blue. HA, hemagglutinin; M, matrix; NA, neuraminidase; NP, nucleoprotein; NS, nonstructural; PA, polymerase acidic; PB, polymerase basic.